Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-(1H-pyrazol-3-yl)-1H-benzimidazole** is a synthetic small molecule compound featuring a benzimidazole core fused to a pyrazole ring. It is primarily characterized as an experimental Aurora kinase A inhibitor, with reported activity against this target in biochemical assays (IC50 ≈910 nM). Aurora kinase A is involved in the regulation of mitosis and cell division, making inhibitors of this enzyme potential candidates for anticancer drug development. However, there are no approved indications or clinical trials beyond preclinical research for this compound[1][4][8]. No commercial brand names or marketed formulations exist.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(1H-pyrazol-3-yl)-1H-benzimidazole.